LeMaitre Vascular (NASDAQ:LMAT) Downgraded to Hold Rating by Wall Street Zen

Posted by George Bondi on Aug 2nd, 2026

Wall Street Zen cut shares of LeMaitre Vascular (NASDAQ:LMAT – Free Report) from a buy rating to a hold rating in a research report sent to investors on Saturday morning.

A number of other research firms have also issued reports on LMAT. Weiss Ratings lowered LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, June 30th. Zacks Research downgraded LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Citigroup reiterated a “market outperform” rating on shares of LeMaitre Vascular in a research report on Tuesday, July 21st. Wells Fargo & Company boosted their price objective on shares of LeMaitre Vascular from $94.00 to $104.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 6th. Finally, Citizens Jmp upped their price objective on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a research report on Wednesday, May 6th. Five investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $112.60.

Check Out Our Latest Report on LeMaitre Vascular

LeMaitre Vascular Stock Performance

NASDAQ LMAT opened at $101.32 on Friday. The firm has a market cap of $2.32 billion, a P/E ratio of 37.39, a P/E/G ratio of 2.81 and a beta of 0.52. LeMaitre Vascular has a 52-week low of $79.00 and a 52-week high of $118.01. The business’s 50-day moving average price is $97.15 and its 200 day moving average price is $99.65. The company has a quick ratio of 12.20, a current ratio of 14.32 and a debt-to-equity ratio of 0.42.

LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.68 EPS for the quarter, beating the consensus estimate of $0.66 by $0.02. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The firm had revenue of $66.55 million during the quarter, compared to the consensus estimate of $66.67 million. During the same period in the prior year, the business earned $0.48 EPS. The firm’s revenue was up 11.1% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. On average, equities research analysts expect that LeMaitre Vascular will post 3 earnings per share for the current year.

Insider Transactions at LeMaitre Vascular

In other news, insider Trent G. Kamke sold 2,928 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $107.00, for a total value of $313,296.00. Following the completion of the sale, the insider directly owned 3,749 shares of the company’s stock, valued at $401,143. This trade represents a 43.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO George W. Lemaitre sold 27,881 shares of the company’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $108.69, for a total value of $3,030,385.89. Following the transaction, the chief executive officer directly owned 1,430,019 shares in the company, valued at $155,428,765.11. This represents a 1.91% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 54,453 shares of company stock valued at $5,906,174. Corporate insiders own 7.40% of the company’s stock.

Hedge Funds Weigh In On LeMaitre Vascular

Large investors have recently made changes to their positions in the stock. M&T Bank Corp boosted its stake in shares of LeMaitre Vascular by 2,240.5% during the 4th quarter. M&T Bank Corp now owns 398,069 shares of the medical instruments supplier’s stock worth $32,283,000 after acquiring an additional 381,061 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of LeMaitre Vascular by 144.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 391,254 shares of the medical instruments supplier’s stock worth $31,731,000 after acquiring an additional 231,157 shares during the period. Bessemer Group Inc. increased its stake in LeMaitre Vascular by 292.3% in the 1st quarter. Bessemer Group Inc. now owns 171,838 shares of the medical instruments supplier’s stock valued at $18,759,000 after purchasing an additional 128,033 shares in the last quarter. Millennium Management LLC increased its stake in LeMaitre Vascular by 119.8% in the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock valued at $17,722,000 after purchasing an additional 115,141 shares in the last quarter. Finally, First Trust Advisors LP raised its holdings in LeMaitre Vascular by 13.4% during the fourth quarter. First Trust Advisors LP now owns 940,140 shares of the medical instruments supplier’s stock worth $76,245,000 after purchasing an additional 111,193 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

(Get Free Report)

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.